年轻高危弥漫大B细胞淋巴瘤患者治疗研究进展 |
| |
引用本文: | 陈溢. 年轻高危弥漫大B细胞淋巴瘤患者治疗研究进展[J]. 白血病.淋巴瘤, 2015, 0(9): 566-569. DOI: 10.3760/cma.j.issn.1009-9921.2015.09.016 |
| |
作者姓名: | 陈溢 |
| |
作者单位: | 福建医科大学附属协和医院血液科 国家临床重点专科 福建省血液病重点实验室 福建省临床重点专科,福州,350001 |
| |
基金项目: | 国家高技术研究发展计划-863计划,卫生行业科研专项项目 |
| |
摘 要: | 弥漫大B细胞淋巴瘤(DLBCL)是成年人淋巴瘤中最常见的一种类型,约占非霍奇金淋巴瘤(NHL)的30%~ 40%.年轻高危DLBCL患者是临床预后不良的一组特殊人群,目前在临床实践中尚无标准治疗方案,常规化疗、联合利妥昔单抗的R-CHOP、R-CHOP样方案、大剂量化疗及自体造血干细胞移植并未完全扭转其预后不良的现实.文章就年轻高危DLBCL患者的治疗现状及未来的治疗方向进行综述.
|
关 键 词: | 弥漫大B细胞淋巴瘤 年轻高危 预后 治疗 |
Treatment progress of young patients with high-risk diffuse large B-cell lymphoma |
| |
Abstract: | Diffuse large B-cell lymphoma (DLBCL) is the most common adult lymphoid malignancy accounting for 30 %-40 % of all non-Hodgkin lymphoma (NHL).Young patients with high-risk DLBCL as a special group with poor clinical prognosis still can not receive standard treatment protocols in clinical practice at present.Conventional chemotherapy, combination of rituximab (R) to conventional CHOP chemotherapy, R-CHOP-like protocol, high-dose chemotherapy and autologous hematopoietic stem cell transplantation have not fully reversed the poor prognosis.This review focuses on the recent advances and future direction in the treatment of the young patients with high-risk DLBCL. |
| |
Keywords: | Diffuse large B-cell lymphoma Young patients High-risk Prognosis Treatment |
本文献已被 万方数据 等数据库收录! |